| editorial | Q871232 |
| scholarly article | Q13442814 |
| P50 | author | Helena J Janse van Rensburg | Q87350758 |
| P2093 | author name string | Xiaolong Yang | |
| P2860 | cites work | Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus | Q24300692 |
| Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus | Q24300770 | ||
| Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells | Q28541763 | ||
| An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer | Q29616732 | ||
| Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis | Q30357776 | ||
| Hearing improvement after bevacizumab in patients with neurofibromatosis type 2 | Q30387415 | ||
| Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling | Q30437229 | ||
| Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside | Q30458310 | ||
| The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals | Q34077795 | ||
| Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought | Q34392256 | ||
| Role of Merlin/NF2 inactivation in tumor biology | Q36189820 | ||
| NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth | Q37275182 | ||
| Molecular insights into NF2/Merlin tumor suppressor function | Q38204110 | ||
| Merlin/NF2-Lin28B-let-7 Is a Tumor-Suppressive Pathway that Is Cell-Density Dependent and Hippo Independent | Q38784652 | ||
| Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin. | Q40484684 | ||
| Nucleocytoplasmic transfer of the NF2 tumor suppressor protein merlin is regulated by exon 2 and a CRM1-dependent nuclear export signal in exon 15. | Q42810615 | ||
| The neurofibromatosis type 2 gene is inactivated in schwannomas | Q43555539 | ||
| Compensative shuttling of merlin to phosphorylation on serine 518 in vestibular schwannoma | Q46909683 | ||
| The Epithelial Circumferential Actin Belt Regulates YAP/TAZ through Nucleocytoplasmic Shuttling of Merlin | Q47972634 | ||
| A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor | Q48129277 | ||
| Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. | Q53316010 | ||
| Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas | Q58862180 | ||
| Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer | Q72610940 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 3533-3536 | |
| P577 | publication date | 2017-10-01 | |
| P1433 | published in | Journal of thoracic disease | Q26841814 |
| P1476 | title | Essential signaling in NF2 loss-related tumours: the therapeutic potential of CRL4DCAF1 and mTOR combined inhibition | |
| P478 | volume | 9 |
Search more.